文献速递眼底病与葡萄膜炎

玻璃体腔注射阿柏西普与贝伐珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿的疗效与注射频率比较

EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
PubMed 文献 · Retina · 2018-01-01

前瞻性随机对照研究比较阿柏西普与贝伐珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿的安全性和疗效。两组各约39-40眼,12个月时黄斑中心凹厚度和最佳矫正视力均显著改善,阿柏西普组注射次数更少、注射间隔更长,视网膜非灌注改善比例更高。结论认为两者疗效相当,但阿柏西普可显著减少频繁注射的负担。

要点

  • 两组12个月时黄斑中心凹厚度和最佳矫正视力均较基线显著改善。
  • 阿柏西普组平均注射次数3.72±2.93次,少于贝伐珠单抗组5.44±2.85次(P<0.05)。
  • 阿柏西普组平均注射间隔54.23±8.47天,长于贝伐珠单抗组35.12±7.76天(P<0.05)。

核心结论

  • 阿柏西普与贝伐珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿疗效相当,无显著并发症。
  • 使用阿柏西普可显著减少频繁玻璃体腔注射的负担。

研究设计与样本

  • 前瞻性、比较性、随机、干预性研究,纳入视网膜中央静脉阻塞继发黄斑水肿眼,按所用玻璃体腔注射药物随机分为两组。
  • A组为玻璃体腔注射阿柏西普组,39例患者,平均年龄57.4±8.2岁;B组为玻璃体腔注射贝伐珠单抗组,40眼,平均年龄56.5±9.1岁。
  • 纳入标准为视网膜中央静脉阻塞继发黄斑水肿且首次注射后随访至少12个月;排除标准为黄斑缺血、合并糖尿病、高血压或肾性视网膜病变、其他视网膜疾病及既往抗血管内皮生长因子注射史。

主要发现

  • 首次注射后12个月,A组黄斑中心凹厚度从475.45±71.05米显著改善至259.11±20.67米,B组从460.22±89.38米显著改善至264.29±32.05米。
  • A组最佳矫正视力从0.81±0.16最小分辨角对数(20/125)显著改善至0.34±0.14最小分辨角对数(20/40),B组从0.73±0.15最小分辨角对数(20/100)显著改善至0.33±0.17最小分辨角对数(20/40)。
  • A组平均注射次数3.72±2.93次,B组5.44±2.85次(P<0.05);A组平均注射间隔54.23±8.47天,B组35.12±7.76天(P<0.05)。
  • 视网膜非灌注改善在A组为9/12眼,B组为3/8眼(P<0.05)。

关键数值与推荐

  • 主要结局指标为黄斑中心凹厚度、最佳矫正视力、注射间隔时间、视网膜非灌注改善及任何报告的并发症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the safety, efficacy, and frequency of intravitreal injection of aflibercept and bevacizumab for treatment of macular edema secondary to central retinal vein occlusion. DESIGN: Prospective, comparative, randomized, interventional study. PATIENTS AND METHODS: Eyes with macular edema secondary to central retinal vein occlusion were randomized between two groups according to the intravitreal injection used. Group A included eyes treated with intravitreal aflibercept, and Group B included eyes treated with intravitreal bevacizumab injections. The inclusion criteria were macular edema secondary to central retinal vein occlusion and follow-up duration of at least 12 months after the first injection. Exclusion criteria were macular ischemia, associated diabetes, hypertensive or renal retinopathy, other retinal disease, and previous anti-vascular endothelial growth factor injection. The main outcome measures are central foveal thickness, best-corrected visual acuity, time intervals between injections, improved retinal nonperfusion, and any reported complication. RESULTS: Group A included 39 patients with a mean age of 57.4 ± 8.2 years. Group B included 40 eyes with a mean age of 56.5 ± 9.1 years. Twelve months after the first injection, central foveal thickness significantly improved from 475.45 ± 71.05 m to 259.11 ± 20.67 m in Group A and from 460.22 ± 89.38 m to 264.29 ± 32.05 m in Group B; best-corrected visual acuity significantly improved from 0.81 ± 0.16 logarithm of the minimum angle of resolution (20/125) to 0.34 ± 0.14 logarithm of the minimum angle of resolution (20/40) in Group A and from 0.73 ± 0.15 logarithm of the minimum angle of resolution (20/100) to 0.33 ± 0.17 logarithm of the minimum angle of resolution (20/40) in Group B; the mean number of injections was 3.72 ± 2.93 in Group A and was 5.44 ± 2.85 in Group B (P < 0.05); and the mean interval between injections was 54.23 ± 8.47 days in Group A and was 35.12 ± 7.76 days in Group B (P < 0.05). Retinal nonperfusion improved in 9/12 eyes in Group A and in 3/8 eyes in Group B (P < 0.05). CONCLUSION: Both aflibercept and bevacizumab are comparably effective for treatment of macular edema secondary to central retinal vein occlusion without significant complications. However, the burden of frequent intravitreal injections could be significantly reduced when using aflibercept.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Lotfy A, Solaiman KAM, Abdelrahman A, et al. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION. Retina. 2018. PMID: 28767552. doi:10.1097/IAE.0000000000001782

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。